Amgen Inc. (NASDAQ:AMGN) Shares Bought by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,594,828 shares of the medical research company’s stock after purchasing an additional 19,053 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 0.30% of Amgen worth $415,676,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Capital Performance Advisors LLP bought a new position in shares of Amgen in the third quarter valued at approximately $25,000. Legacy Investment Solutions LLC bought a new position in Amgen during the 3rd quarter valued at $29,000. Matrix Trust Co acquired a new position in shares of Amgen during the 3rd quarter valued at $36,000. Heck Capital Advisors LLC acquired a new position in shares of Amgen during the 4th quarter valued at $36,000. Finally, Livelsberger Financial Advisory bought a new stake in shares of Amgen in the 3rd quarter worth $56,000. 76.50% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.69% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of research analyst reports. Leerink Partners lowered their target price on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Bank of America lifted their price objective on shares of Amgen from $256.00 to $275.00 and gave the stock an “underperform” rating in a research note on Thursday. Truist Financial cut their target price on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research note on Wednesday, January 8th. Redburn Partners decreased their price target on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Amgen currently has an average rating of “Hold” and an average target price of $314.83.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $297.78 on Friday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The stock has a market capitalization of $160.07 billion, a P/E ratio of 38.13, a P/E/G ratio of 2.87 and a beta of 0.56. The business has a 50-day moving average of $271.69 and a two-hundred day moving average of $303.55. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 168.35% and a net margin of 13.00%. On average, equities research analysts predict that Amgen Inc. will post 19.56 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.20%. Amgen’s payout ratio is presently 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.